Since new information is coming out about the safety of frequently used medications, pharmacists need to review this information with regard to previously published information and discuss how to apply the new information to the current patient population.
The CPE discussion is available at: https://youtu.be/qyzZU_Riug4
The disclosure policies of the SIUE School of Pharmacy Office of Continuing Professional Education requires all persons in a position to control content to disclose any relevant financial relationships with commercial interests. If a conflict is identified, the Office of Professional Continuing Education will initiate a process for resolving the conflict. The existence of relationships does not necessarily imply bias or lessen the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The persons required to disclose conflicts include all course faculty, the SIUE CPE administrator, all activity planners and all reviewers. The relevant commercial financial relationships or affiliations must have occured over the past 12 months.
The participant must provide the correct NABP ePID number/DOB combination in their electronic profile. All CPE evaluations must be completed within 60 days of completing the activity. It is the participant's responsibility to check that their credit records are correct within the 60 day period after completion of the activity. Log in to CPE Monitor at www.mycpemonitor.net to view a list of all ACPE-accredited activities you have taken. Any discrepancies must be resolved with the CPE Provider directly and in a timely manner.
Requirements for CE Credit
Participants must complete the exercise, the post-test questions and the online evaluation to receive credit.
There are low palliative care referrals among hematologic malignancy patients. The goal of this CPE is to raise awareness among pharmacists of the unmet palliative care needs of hematologic malignancies.
Course Link: https://youtu.be/qyzZU_Riug4
- Describe the pharmacologic mechanisms of haloperidol and lorazepam for the treatment of agitated delirium
- Discuss recent trial using haloperidol or risperidone for delirium in palliative care patients
- Discuss background, methods, results, and clinical impact of the article presented
Christopher John Walczak, Pharm.D.
Brief Bio : Dr. Walczak is a PGY2 Resident at Riverside Memorial Hospital in Columbus Ohio. He completed his B.S. in Chemistry at Miami University (Ohio) and earned his Pharm.D. degree from The Ohio State University.
Release Date: Dec 19, 2017
Credit Expiration Date: Dec 19, 2020